"Top rated cancer treatment center in Canton, Ohio. Gabrail Cancer Center is a one stop shop for cancer treatment, with an in-house pharmacy, cancer treatment center, CT scanner, primary care clinic, and lab there is not much need to go for outside services. The majority of your care will all take place in one convenient building. GCC is also no stranger to clinical trial options. The center boasts an extensive list of clinical trials for patients that are interested. Known for it's quick scheduling, the center is committed to making sure patients are seen with in 48 hours. Call to schedule your appointment now 330-492-3345"

During the past decade, Gabrail Cancer Center conducted 163 clinical trials. In the 10-year time frame, 163 clinical trials started and 78 clinical trials were completed, i.e. on average, 47.9% percent of trials that started reached the finish line to date. In the past 5 years, 89 clinical trials started and 40 clinical trials were completed. i.e. 44.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gabrail Cancer Center" #1 sponsor was "Celgene" with 14 trials, followed by "Amgen" with 9 trials sponsored, "Karyopharm Therapeutics Inc" with 7 trials sponsored, "Bristol-Myers Squibb" with 6 trials sponsored and "Genentech, Inc." with 6 trials sponsored. Other sponsors include 239 different institutions and companies that sponsored additional 168 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gabrail Cancer Center" #1 collaborator was "Merck Sharp & Dohme LLC" with 10 trials as a collaborator, "ARMO BioSciences" with 3 trials as a collaborator, "Amgen" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator and "ICON Clinical Research" with 3 trials as a collaborator. Other collaborators include 41 different institutions and companies that were collaborators in the rest 45 trials.

According to Clinical.Site data, the most researched conditions in "Gabrail Cancer Center" are "Multiple Myeloma" (21 trials), "Cancer" (11 trials), "Non Small Cell Lung Cancer" (11 trials), "Myelodysplastic Syndromes" (10 trials) and "Acute Myeloid Leukemia" (9 trials). Many other conditions were trialed in "Gabrail Cancer Center" in a lesser frequency.

Most popular intervention types in "Gabrail Cancer Center" are "Drug" (262 trials), "Biological" (29 trials), "Other" (10 trials), "Device" (3 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (26 trials), "Dexamethasone" (14 trials), "Carboplatin" (10 trials), "Docetaxel" (10 trials) and "Gemcitabine" (10 trials). Other intervention names were less common.

The vast majority of trials in "Gabrail Cancer Center" are 262 trials for "All" genders, 13 trials for "Male" genders and 10 trials for "Female" genders.

Currently, there are 101 active trials in "Gabrail Cancer Center". 1 are not yet recruiting, 74 are recruiting, 25 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 115 completed trials in Gabrail Cancer Center, undefined suspended trials, and 52 terminated clinical trials to date.

Out of the total trials that were conducted in Gabrail Cancer Center, 109 "Phase 1" clinical trials were conducted, 133 "Phase 2" clinical trials and 78 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".